SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MLTX is trending due to discussion around mixed Phase 3 trial data for their skin disease drug, with community members debating the severity of the results and potential for a rebound. Some believe the selloff is an overreaction, citing the company's cash position and institutional ownership, while others point to concerns about the drug's efficacy compared to competitors. Speculation about a potential Merck buyout continues to fuel some of the interest.

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

Dogwood Therapeutics Inc.

Dogwood Therapeutics is trending as traders discuss its recent exclusive worldwide license for a cancer pain treatment, with many highlighting its low float and potential for a short squeeze. The community is actively speculating on price targets and anticipating further volatility, focusing on potential breakout levels. Some traders cite upcoming catalysts, including Fibromyalgia/partnership news late in Q4.

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

GLD is trending as gold prices rally, fueled by anticipation of Federal Reserve rate cuts and safe-haven demand amidst global economic and political uncertainty. Community members are actively discussing whether the current rally is sustainable, with some pointing to overbought conditions and potential pullbacks, while others remain bullish due to the weakening dollar and central bank activity. Broader market context includes discussions around inflation, currency devaluation, and comparisons to other asset classes like Bitcoin.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the crypto community focuses on its potential to represent and revolutionize cannabis culture. Discussions highlight Weedcoin's mission to foster a positive community and bridge culture with cryptocurrency. Some traders are speculating about potential catalysts from cannabis-related news and broader discussions around the future of the cannabis industry.

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Larimar Therapeutics is trending due to a significant pre-market slump triggered by reports of a high anaphylaxis rate in a drug study, specifically seven patients experiencing anaphylaxis and withdrawing from a long-term study. The community is torn between concerns about the side effects and optimism about the drug's potential, with some viewing the drop as an overreaction and a buying opportunity, while others are exiting their positions. Despite the setback, some believe the FDA's continued involvement suggests the program is not stalled and that the data still signals great potential.

JFB Construction Holdings is a commercial and residential real estate construction and development company, which engages in delivering services to commercial and residential markets. It operates through the following segments: Commercial Construction, Residential Construction, and Real Estate Development. The Commercial Construction segment includes all activities related to the construction of commercial properties. The Residential Construction segment focuses on the construction of residential properties including single-family homes and multi-family units. The Real Estate Development segment refers to the acquisition, development, and sale of real estate properties. The company was founded by Joseph F. Basille III on April 9, 2024 and is headquartered in Lantana, FL.

JFB Construction Holdings - Ordinary Shares - Class A

JFB is trending due to a recently announced $44 million private placement, sparking discussions about its potential impact on the company's liquidity and future prospects. The community is actively debating the merits of the deal, with some focusing on the low float and potential for a squeeze, while others express concern about possible dilution. Breakout levels are being closely watched as the stock experiences high volume and volatility.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is trending due to its acquisition of a UK rare earth metals producer, sparking bullish sentiment and discussions about potential price targets. The community is actively debating the significance of this expansion and whether it can push the stock to new all-time highs. Broader discussions touch on the strategic importance of rare earth minerals and potential government support for domestic suppliers.

Electronic Arts, Inc. engages in the development, marketing, publication, and distribution of games, content, and services for game consoles, PCs, mobile phones, and tablets. The company develops and publishes games and services across various genres, such as sports, first-person shooter, action, role-playing, and simulation primarily under the Battlefield, The Sims, Apex Legends, Anthem, Need for Speed, and Plants v. Zombies brands, and license games, including FIFA, Madden NFL, and Star Wars brands. The firm also provides advertising services and licenses its games to third parties to distribute and host its games. It markets and sells its games and services through digital distribution channels, as well as through retail channels, such as mass-market retailers, electronics specialty stores, and game software specialty stores. The company was founded by William M. Hawkins III and William Gordon in 1982 and is headquartered in Redwood City, CA.

Electronic Arts, Inc.

Electronic Arts is trending due to reports of a potential $50 billion privatization deal, which sent the stock surging. The community is actively discussing the buyout price and potential impact on current shareholders. Some are also speculating about the future direction of the company and its games should the deal go through.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X is trending as the community rallies around the meme-based token on the Solana blockchain, emphasizing its longevity and status as a Jupiter Strict List token. Community members are playfully engaging with the 'What's UpDog?' joke, fostering a lighthearted atmosphere while encouraging others to 'load' the token. The focus remains on community-building and shared humor within the $UPDOG.X ecosystem.

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Barrick Mining ($B) is trending due to a leadership transition and positive sentiment around gold prices potentially reaching $4,000, with community members speculating on how this will affect the stock. Some are also discussing unusual options activity and anticipating a resolution to the Mali situation, while others highlight the company's growth potential with new projects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BELLUS Health is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys. The lead program KIACTAâ?¢, a novel drug candidate, is in data review after announcing on June 20, 2016 top-line results from its Phase 3 study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is partnered with global private equity firm Auven Therapeutics for the development of KIACTAâ?¢. KIACTAâ?¢ is also being developed as a treatment in a second indication called sarcoidosis, a rare, potentially fatal inflammatory condition that affects the lungs. An investigational new drug application (IND) for a Phase 2/3 clinical study is expected to be filed with the U.S. Food and Drug Administration in 2016. In addition, BELLUS Health is developing Shigamabâ?¢, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS). sHUS often leads to dialysis, chronic kidney disease and in some cases death, particularly in children. Shigamabâ?¢ pre-clinical studies for the treatment of sHUS are currently underway.  BELLUS Healthâ??s pipeline also includes a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body.

Bellus Health Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '23	-$0.21	--	--	N/A
Q1 '23	-$0.19	-$0.20	-5.26%	MISSED

BLU
Bellus Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '23

Historical Earnings

Latest BLU News

BLU Bellus Health Inc